{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:15:19Z","timestamp":1787883319922,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1160011"],"award-info":[{"award-number":["GNT1160011"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["DONNEL21GO"],"award-info":[{"award-number":["DONNEL21GO"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Lentiviral vectors are attractive delivery vehicles for cystic fibrosis gene therapy owing to their low immunogenicity and ability to integrate into the host cell genome, thereby producing long-term, stable gene expression. Nonetheless, repeat dosing may be required to increase initial expression levels, and\/or boost levels when they wane. The primary aim of this study was to determine if repeat dosing of a VSV-G pseudotyped LV vector delivered into mouse lungs is more effective than a single dose. C57Bl\/6 mouse lungs were conditioned with lysophosphatidylcholine, followed one-hour later by a LV vector carrying the\n                    <jats:italic>luciferase<\/jats:italic>\n                    reporter gene, using six different short-term (\u22641 wk) and long-term (&gt;1 wk) dosing schedules. Luciferase expression was quantified using bioluminescence imaging over 12 months. Most dosing schedules produced detectable bioluminescence over the 12-month period, but the shorter intervals (\u22641 wk) produced higher levels of flux than the longest interval (five doses at least 1-month apart). Ex vivo lung analysis at 12 months showed that the estimated mean flux for the group that received two doses 1-week apart was significantly greater than the single dose group and the two groups that received doses over a period greater than 1-week. These results suggest that early consecutive multiple doses are more effective at improving gene expression in mouse lungs at 12 months, than longer repeat dosing intervals.\n                  <\/jats:p>","DOI":"10.1038\/s41434-023-00403-3","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T08:02:00Z","timestamp":1683705720000},"page":"698-705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Repeat or single-dose lentiviral vector administration to mouse lungs? It\u2019s all about the timing"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5320-7756","authenticated-orcid":false,"given":"Martin","family":"Donnelley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2236-9410","authenticated-orcid":false,"given":"Patricia","family":"Cmielewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantelle","family":"Carpentieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6045-3998","authenticated-orcid":false,"given":"Alexandra","family":"McCarron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Rout-Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1746-3290","authenticated-orcid":false,"given":"David","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Farrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"403_CR1","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","volume":"397","author":"M Shteinberg","year":"2021","unstructured":"Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021;397:2195\u2013211.","journal-title":"Lancet"},{"key":"403_CR2","doi-asserted-by":"publisher","first-page":"648203","DOI":"10.3389\/fphar.2021.648203","volume":"12","author":"J Mercier","year":"2021","unstructured":"Mercier J, Ruffin M, Corvol H, Guillot L. Gene therapy: a possible alternative to CFTR modulators? Front Pharmacol. 2021;12:648203.","journal-title":"Front Pharmacol"},{"key":"403_CR3","doi-asserted-by":"publisher","first-page":"200016","DOI":"10.1183\/20734735.0016-2020","volume":"16","author":"S Cuevas-Oca\u00f1a","year":"2020","unstructured":"Cuevas-Oca\u00f1a S, Laselva O, Avolio J, Nenna R. The era of CFTR modulators: improvements made and remaining challenges. Breathe. 2020;16:200016.","journal-title":"Breathe."},{"key":"403_CR4","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","volume":"201","author":"P-R Burgel","year":"2020","unstructured":"Burgel P-R, Munck A, Durieu I, Chiron R, Mely L, Prevotat A, et al. Real-life safety and effectiveness of lumacaftor\u2013ivacaftor in patients with cystic fibrosis. Am J Respir Crit Care Med. 2020;201:188\u201397.","journal-title":"Am J Respir Crit Care Med"},{"key":"403_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03099-4","volume":"19","author":"J-A Lee","year":"2021","unstructured":"Lee J-A, Cho A, Huang EN, Xu Y, Quach H, Hu J, et al. Gene therapy for cystic fibrosis: new tools for precision medicine. J Transl Med. 2021;19:452.","journal-title":"J Transl Med"},{"key":"403_CR6","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1186\/s13287-020-01950-x","volume":"11","author":"H Meyer-Berg","year":"2020","unstructured":"Meyer-Berg H, Zhou Yang L, Pilar de Lucas M, Zambrano A, Hyde SC, Gill DR. Identification of AAV serotypes for lung gene therapy in human embryonic stem cell-derived lung organoids. Stem Cell Res Ther. 2020;11:448.","journal-title":"Stem Cell Res Ther"},{"key":"403_CR7","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3389\/fphar.2018.01381","volume":"9","author":"M Donnelley","year":"2018","unstructured":"Donnelley M, Parsons DW. Gene therapy for cystic fibrosis lung disease: overcoming the barriers to translation to the clinic. Front Pharmacol. 2018;9:1381.","journal-title":"Front Pharmacol"},{"key":"403_CR8","doi-asserted-by":"publisher","first-page":"R88","DOI":"10.1093\/hmg\/ddz139","volume":"28","author":"Z Yan","year":"2019","unstructured":"Yan Z, McCray PB Jr, Engelhardt JF. Advances in gene therapy for cystic fibrosis lung disease. Hum Mol Genet. 2019;28:R88\u2013R94.","journal-title":"Hum Mol Genet"},{"key":"403_CR9","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1089\/hum.2017.059","volume":"29","author":"N Farrow","year":"2018","unstructured":"Farrow N, Donnelley M, Cmielewski P, Roscioli E, Rout-Pitt N, McIntyre C, et al. Role of basal cells in producing persistent lentivirus-mediated airway gene expression. Hum Gene Ther. 2018;29:653\u201362.","journal-title":"Hum Gene Ther"},{"key":"403_CR10","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1089\/hum.2021.031","volume":"32","author":"C Carpentieri","year":"2021","unstructured":"Carpentieri C, Farrow N, Cmielewski P, Rout-Pitt N, McCarron A, Knight E, et al. The effects of conditioning and lentiviral vector pseudotype on short- and long-term airway reporter gene expression in mice. Hum Gene Ther. 2021;32:817\u201327.","journal-title":"Hum Gene Ther"},{"key":"403_CR11","doi-asserted-by":"crossref","unstructured":"Maurya, S, Sarangi, P & Jayandharan, G.R. Safety of Adeno-associated virus-based vector-mediated gene therapy\u2014impact of vector dose. Cancer Gene Ther 2022;29:1305\u20136.","DOI":"10.1038\/s41417-021-00413-6"},{"key":"403_CR12","doi-asserted-by":"publisher","first-page":"12818","DOI":"10.1128\/JVI.79.20.12818-12827.2005","volume":"79","author":"PL Sinn","year":"2005","unstructured":"Sinn PL, Burnight ER, Hickey MA, Blissard GW, McCray PB. Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer. J Virol. 2005;79:12818\u201327.","journal-title":"J Virol"},{"key":"403_CR13","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/mt.2010.13","volume":"18","author":"K Mitomo","year":"2010","unstructured":"Mitomo K, Griesenbach U, Inoue M, Somerton L, Meng C, Akiba E, et al. Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with sendai virus envelopes. Mol Ther. 2010;18:1173\u201382.","journal-title":"Mol Ther"},{"key":"403_CR14","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1164\/rccm.201206-1056OC","volume":"186","author":"U Griesenbach","year":"2012","unstructured":"Griesenbach U, Inoue M, Meng C, Farley R, Chan M, Newman NK, et al. Assessment of F\/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy. Am J Respir Crit Care Med. 2012;186:846\u201356.","journal-title":"Am J Respir Crit Care Med"},{"key":"403_CR15","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/jgm.1368","volume":"11","author":"AG Stocker","year":"2009","unstructured":"Stocker AG, Kremer KL, Koldej R, Miller DS, Anson DS, Parsons DW. Single-dose lentiviral gene transfer for lifetime airway gene expression. J Gene Med. 2009;11:861\u20137.","journal-title":"J Gene Med"},{"key":"403_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jgm.2778","volume":"16","author":"P Cmielewski","year":"2014","unstructured":"Cmielewski P, Donnelley M, Parsons DW. Long-term therapeutic and reporter gene expression in lentiviral vector treated cystic fibrosis mice. J Gene Med. 2014;16:291\u20139.","journal-title":"J Gene Med"},{"key":"403_CR17","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1089\/hum.2006.17.440","volume":"17","author":"CL Halbert","year":"2006","unstructured":"Halbert CL, Miller AD, McNamara S, Emerson J, Gibson RL, Ramsey B, et al. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: implications for gene therapy using AAV vectors. Hum Gene Ther. 2006;17:440\u20137.","journal-title":"Hum Gene Ther"},{"key":"403_CR18","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1080\/14712598.2017.1347630","volume":"17","author":"WB Guggino","year":"2017","unstructured":"Guggino WB, Cebotaru L. Adeno-associated virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments. Expert Opin Biol Ther. 2017;17:1265\u201373.","journal-title":"Expert Opin Biol Ther"},{"key":"403_CR19","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1128\/JVI.74.3.1524-1532.2000","volume":"74","author":"CL Halbert","year":"2000","unstructured":"Halbert CL, Rutledge EA, Allen JM, Russell DW, Miller AD. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol. 2000;74:1524\u201332.","journal-title":"J Virol"},{"key":"403_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","volume":"122","author":"F Mingozzi","year":"2013","unstructured":"Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013;122:23\u201336.","journal-title":"Blood."},{"key":"403_CR21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.2174\/156652307782151515","volume":"7","author":"A Follenzi","year":"2007","unstructured":"Follenzi A, Santambrogio L, Annoni A. Immune responses to lentiviral vectors. Curr Gene Ther. 2007;7:306\u201315.","journal-title":"Curr Gene Ther"},{"key":"403_CR22","doi-asserted-by":"publisher","first-page":"10684","DOI":"10.1128\/JVI.00227-08","volume":"82","author":"PL Sinn","year":"2008","unstructured":"Sinn PL, Arias AC, Brogden KA, McCray PB. Lentivirus vector can be readministered to nasal epithelia without blocking immune responses. J Virol. 2008;82:10684\u201392.","journal-title":"J Virol."},{"key":"403_CR23","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","volume":"18","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLOS Biol. 2020;18:e3000410.","journal-title":"PLOS Biol"},{"key":"403_CR24","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.14440\/jbm.2018.236","volume":"5","author":"N Rout-Pitt","year":"2018","unstructured":"Rout-Pitt N, McCarron A, McIntyre C, Parsons D, Donnelley M. Large-scale production of lentiviral vectors using multilayer cell factories. J Biol Methods. 2018;5:e90.","journal-title":"J Biol Methods"},{"key":"403_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1089\/hgtb.2019.038","volume":"30","author":"A McCarron","year":"2019","unstructured":"McCarron A, Donnelley M, McIntyre C, Parsons D. Transient lentiviral vector production using a packed-bed bioreactor system. Hum Gene Ther Methods. 2019;30:93\u2013101.","journal-title":"Hum Gene Ther Methods"},{"key":"403_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/01902148.2017.1395931","volume":"43","author":"P Cmielewski","year":"2017","unstructured":"Cmielewski P, Farrow N, Devereux S, Parsons D, Donnelley M. Gene therapy for cystic fibrosis: improved delivery techniques and conditioning with lysophosphatidylcholine enhance lentiviral gene transfer in mouse lung airways. Exp Lung Res. 2017;43:426\u201333.","journal-title":"Exp Lung Res"},{"key":"403_CR27","unstructured":"Pinheiro J, Bates D, DebRoy S, Sarkar D, R Core Team. Linear and nonlinear mixed effects models. R package version 3.1\u2013147. 2020."},{"key":"403_CR28","unstructured":"R Core Team. A language and environment for statistical computing. R Foundation for Statisitical Computing. Vienna, Austria. 2019."},{"key":"403_CR29","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1242\/dev.02407","volume":"133","author":"EL Rawlins","year":"2006","unstructured":"Rawlins EL, Hogan BLM. Epithelial stem cells of the lung: privileged few or opportunities for many? Development. 2006;133:2455\u201365.","journal-title":"Development."}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-023-00403-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-023-00403-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-023-00403-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T19:07:32Z","timestamp":1695064052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-023-00403-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["403"],"URL":"https:\/\/doi.org\/10.1038\/s41434-023-00403-3","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"assertion":[{"value":"1 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}